National Breast Cancer Coalition Steps up Washington Lobbying

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

WASHINGTON--The National Breast Cancer Coalition (NBCC) has announced its intention to lobby against congressional forces that want to reduce NIH funding. The coalition thus allies itself with professional societies that lobby Congress to increase federal funding for biomedical research.

WASHINGTON--The National Breast Cancer Coalition (NBCC) has announcedits intention to lobby against congressional forces that wantto reduce NIH funding. The coalition thus allies itself with professionalsocieties that lobby Congress to increase federal funding forbiomedical research.

The Coalition also plans to draft legislation designed to protectthe privacy of individuals who test positive for the presenceof cancer genes so that their access to health insurance coveragewill not be put in jeopardy.

Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content